171 related articles for article (PubMed ID: 21471986)
1. Inhibition of glycogen synthase kinase-3 increases the cytotoxicity of enzastaurin.
Rovedo MA; Krett NL; Rosen ST
J Invest Dermatol; 2011 Jul; 131(7):1442-9. PubMed ID: 21471986
[TBL] [Abstract][Full Text] [Related]
2. The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway.
Querfeld C; Rizvi MA; Kuzel TM; Guitart J; Rademaker A; Sabharwal SS; Krett NL; Rosen ST
J Invest Dermatol; 2006 Jul; 126(7):1641-7. PubMed ID: 16645590
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of protein kinase Cbeta by enzastaurin enhances radiation cytotoxicity in pancreatic cancer.
Spalding AC; Watson R; Davis ME; Kim AC; Lawrence TS; Ben-Josef E
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6827-33. PubMed ID: 18006785
[TBL] [Abstract][Full Text] [Related]
4. The serine-threonine kinase p90RSK is a new target of enzastaurin in follicular lymphoma cells.
Kheirallah S; Fruchon S; Ysebaert L; Blanc A; Capilla F; Marrot A; Alsaati T; Frenois FX; Benhadji KA; Fournié JJ; Laurent G; Bezombes C
Br J Pharmacol; 2013 Dec; 170(7):1374-83. PubMed ID: 23992368
[TBL] [Abstract][Full Text] [Related]
5. The anti-tumoral drug enzastaurin inhibits natural killer cell cytotoxicity via activation of glycogen synthase kinase-3β.
Ogbomo H; Biru T; Michaelis M; Loeschmann N; Doerr HW; Cinatl J
Biochem Pharmacol; 2011 Jan; 81(2):251-8. PubMed ID: 20934407
[TBL] [Abstract][Full Text] [Related]
6. Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells.
Tekle C; Giovannetti E; Sigmond J; Graff JR; Smid K; Peters GJ
Br J Cancer; 2008 Sep; 99(5):750-9. PubMed ID: 18728666
[TBL] [Abstract][Full Text] [Related]
7. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418.
Bhat R; Xue Y; Berg S; Hellberg S; Ormö M; Nilsson Y; Radesäter AC; Jerning E; Markgren PO; Borgegård T; Nylöf M; Giménez-Cassina A; Hernández F; Lucas JJ; Díaz-Nido J; Avila J
J Biol Chem; 2003 Nov; 278(46):45937-45. PubMed ID: 12928438
[TBL] [Abstract][Full Text] [Related]
8. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.
Lee KW; Kim SG; Kim HP; Kwon E; You J; Choi HJ; Park JH; Kang BC; Im SA; Kim TY; Kim WH; Bang YJ
Cancer Res; 2008 Mar; 68(6):1916-26. PubMed ID: 18339873
[TBL] [Abstract][Full Text] [Related]
9. Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines.
Rizvi MA; Ghias K; Davies KM; Ma C; Weinberg F; Munshi HG; Krett NL; Rosen ST
Mol Cancer Ther; 2006 Jul; 5(7):1783-9. PubMed ID: 16891464
[TBL] [Abstract][Full Text] [Related]
10. Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells.
Serova M; Astorgues-Xerri L; Bieche I; Albert S; Vidaud M; Benhadji KA; Emami S; Vidaud D; Hammel P; Theou-Anton N; Gespach C; Faivre S; Raymond E
Mol Cancer Ther; 2010 May; 9(5):1308-17. PubMed ID: 20406951
[TBL] [Abstract][Full Text] [Related]
11. New methods to control neuroblastoma growth.
Dent P
Cancer Biol Ther; 2014 May; 15(5):481-2. PubMed ID: 24618834
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines.
Vogl UM; Berger W; Micksche M; Pirker C; Lamm W; Pichelmeyer O; Zielinski CC; Schmidinger M
Cancer Lett; 2009 May; 277(2):218-26. PubMed ID: 19171421
[TBL] [Abstract][Full Text] [Related]
13. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.
Graff JR; McNulty AM; Hanna KR; Konicek BW; Lynch RL; Bailey SN; Banks C; Capen A; Goode R; Lewis JE; Sams L; Huss KL; Campbell RM; Iversen PW; Neubauer BL; Brown TJ; Musib L; Geeganage S; Thornton D
Cancer Res; 2005 Aug; 65(16):7462-9. PubMed ID: 16103100
[TBL] [Abstract][Full Text] [Related]
14. Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth.
Carter YM; Kunnimalaiyaan S; Chen H; Gamblin TC; Kunnimalaiyaan M
Cancer Biol Ther; 2014 May; 15(5):510-5. PubMed ID: 24521712
[TBL] [Abstract][Full Text] [Related]
15. Correlations of mRNA expression and in vitro chemosensitivity to enzastaurin in freshly explanted human tumor cells.
Hanauske AR; Eismann U; Oberschmidt O; Pospisil H; Hanauske-Abel HM; Blatter J; Ma D; Chen V; Lahn M
Invest New Drugs; 2008 Jun; 26(3):215-22. PubMed ID: 18000644
[TBL] [Abstract][Full Text] [Related]
16. The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines.
Neri A; Marmiroli S; Tassone P; Lombardi L; Nobili L; Verdelli D; Civallero M; Cosenza M; Bertacchini J; Federico M; De Pol A; Deliliers GL; Sacchi S
Leuk Lymphoma; 2008 Jul; 49(7):1374-83. PubMed ID: 18452078
[TBL] [Abstract][Full Text] [Related]
17. The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.
Wu X; Zhu M; Fletcher JA; Giobbie-Hurder A; Hodi FS
PLoS One; 2012; 7(1):e29622. PubMed ID: 22253748
[TBL] [Abstract][Full Text] [Related]
18. Glycogen synthase kinase 3-specific inhibitor AR-A014418 decreases neuropathic pain in mice: evidence for the mechanisms of action.
Mazzardo-Martins L; Martins DF; Stramosk J; Cidral-Filho FJ; Santos AR
Neuroscience; 2012 Dec; 226():411-20. PubMed ID: 23000630
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Glycogen Synthase Kinase Inhibitors That Regulate Cytochrome P450 Expression in Primary Human Hepatocytes by Activation of β-Catenin, Aryl Hydrocarbon Receptor and Pregnane X Receptor Signaling.
Briolotti P; Chaloin L; Balaguer P; Da Silva F; Tománková V; Pascussi JM; Duret C; Fabre JM; Ramos J; Klieber S; Maurel P; Daujat-Chavanieu M; Gerbal-Chaloin S
Toxicol Sci; 2015 Nov; 148(1):261-75. PubMed ID: 26259606
[TBL] [Abstract][Full Text] [Related]
20. Glycogen synthase kinase-3beta (GSK-3beta) inhibitors AR-A014418 and B6B3O prevent human immunodeficiency virus-mediated neurotoxicity in primary human neurons.
Nguyen TB; Lucero GR; Chana G; Hult BJ; Tatro ET; Masliah E; Grant I; Achim CL; Everall IP;
J Neurovirol; 2009 Sep; 15(5-6):434-8. PubMed ID: 19688630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
